Kintara shareholders approve increase in authorized common shares from 5.5M to 75M

As described under Proposal 2 of Item 5.07 of this Current Report, on June 30, 2023, the stockholders of Kintara Therapeutics, Inc. (the “Company”) voted at the Company’s reconvened 2023 Annual Meeting of Stockholders (the “Annual Meeting”), which was adjourned on May 8, 2023, May 25, 2023 and June 15, 2023, to approve an amendment to the Company’s Articles of Incorporation, as amended (the “Articles of Incorporation”), to increase the number of authorized shares of common stock, par value of $0.001 per share (“Common Stock”) from 5,500,000 to 75,000,000 shares.

3. The votes cast with respect to the proposal to approve an adjournment of the Annual Meeting in the event that the number of shares of Common Stock and Series C Preferred Stock present or represented by proxy at the Annual Meeting and voting “FOR” the adoption of the Charter Amendment Proposal were insufficient were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES 1,025,325 187,720 25,581 0 The stockholders approved the proposal to adjourn the Annual Meeting if needed.

4. The votes cast with respect to the proposal to ratify the appointment of Marcum LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending June 30, 2023 were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES 1,193,957 32,888 11,781 0 The stockholders approved the proposal to ratify the appointment of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2023.

2. The votes cast with respect to the proposal to adopt an amendment to the Articles of Incorporation to increase the number of shares of Common Stock available for issuance thereunder from 5,500,000 to 75,000,000 shares were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES 970,365 264,177 4,084 0 The stockholders approved the proposal to adopt the amendment to the Articles of Incorporation.

The voting results for each item of business voted upon at the Annual Meeting were as follows: 1. The proposal to elect the following nominees, Robert E. Hoffman, Robert J. Toth, Jr., Laura Johnson, and Tamara A. Favorito, as directors of the Company to hold office until the next annual meeting and until his or her successor has been duly elected and qualified, or, if sooner, until the director’s death, resignation or removal. FOR WITHHELD BROKER NON-VOTES Robert E. Hoffman 809,194 56,121 373,311 Robert J. Toth, Jr. 803,679 61,636 373,311 Laura Johnson 806,691 58,624 373,311 Tamara A. Favorito 806,805 58,510 373,311 The stockholders elected each nominee as a director of the Company.